Allergic Conjunctivitis Market, By Type (Bacterial, Allergic, Viral, and Chemical), By Drug Class (Antibiotics, Mast Cell Stabilizers, Steroids, and Others), By End Users (Hospitals and Clinics and Specialty Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2029

The rise in air pollution in major cities worldwide is another factor driving the global market for treatments for allergic conjunctivitis. The National Center for Biotechnology Information (NCBI) published a study in 2016 that showed how weather variations and ambient air pollution cause allergic conjunctivitis to occur and worsen. This phenomenon is explained by the conjunctiva's sensitivity to environmental particles and its direct interaction with the external environment. Thus, the global market for treatments for allergic conjunctivitis is driven by the increase in air pollution.

Development of new treatment options

Pharmaceutical companies are working on developing Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP as new treatments for allergic conjunctivitis. For example, a phase 3 clinical trial is presently investigating the efficacy of EyeMax LLC's EM-100 in treating ocular itching. Approximately two thirds of novel treatment options are currently undergoing phase 2 or phase 3 clinical trials. Major pharmaceutical companies are funding all of these studies. The market for treatments for allergic conjunctivitis is expanding worldwide thanks to these factors. Moreover, factors like a proper diagnosis of viral conjunctivitis and a lack of knowledge about cutting-edge technologies are impeding the global market's growth.